Tryptamine Therapeutics Ltd. Stock Analysis TYP.AX

Tryptamine Therapeutics Ltd. is a clinical-stage biotechnology company, which engages in investing in biopharmaceutical drug development. The firm is focused on developing proprietary, novel formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs. The company is focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. Its lead program, TRP-8803, is a proprietary formulation of IV-infused psilocin (the active metabolite of psilocybin) with potential to alleviate numerous shortcomings of oral psilocybin It intends to accomplish this through the development of an IV infusion of psilocin Its lead programs are designed to address neuropsychiatric disorders through the therapeutic dosing of synthetic psilocybin and IV infused psilocin in conjunction with psychotherapy. The company has completed phase II clinical trials for the treatment of binge eating disorder. Its pipeline products include TRP-8803 and TRP-8802.